Navigation Links
Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Date:12/13/2007

Oral Presentation of the US Oncology Adjuvant Trial 9735 at 2007 San Antonio Breast Cancer Symposium Showed Taxotere(R) and Cyclophosphamide

Improved Overall Survival Versus An Anthracycline Combination

SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ -- Results presented at the 30th annual San Antonio Breast Cancer Symposium (SABCS) showed that for women with early stage breast cancer who have had surgery, treatment with the investigational chemotherapy combination of Taxotere(R) (docetaxel) Injection Concentrate and cyclophosphamide significantly improved overall survival compared to standard chemotherapy. The presentation reports results with a median follow-up of seven years and has been updated since the last report was published with 5.5 years median follow-up [Jones S et al. J Clin Oncol, 2006, 24:5381-7]. This latest report has also been updated from the abstract submitted to SABCS 2007.

In the updated analysis, overall survival at seven years was statistically higher among women treated with Taxotere(R) and cyclophosphamide (TC) versus those treated with doxorubicin and cyclophosphamide (AC): 87% versus 82% (HR: 0.69, [95% CI, 0.50, 0.97]). The 31% reduction in the risk of death was statistically significant (p=0.032). At seven years, the disease-free survival (DFS) was also statistically greater among women treated with TC than those treated with AC: 81% versus 75% (HR: 0.74, [95% CI, 0.56, 0.98]). The 26% reduction in the risk of cancer recurrence among women treated with TC was statistically significant (p=0.033). The disease-free survival benefit seen in the elderly patients (aged 65 years or older; 31% risk reduction of recurrence) is consistent with that in the overall patient population.

Principal study investigator Dr. Stephen Jones, medical director and co-chair, breast cancer research committee of US Oncology, helped develop the regimen combining the anthracycline doxorubicin with cyclophosphamide, which became a
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
2. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
3. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
4. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
5. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
6. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
9. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
10. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
11. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Oxford Finance LLC ("Oxford"), a specialty finance ... healthcare services companies, today announced the closing of a ... Inc., a diagnostic testing company focused on improving the ... and improved outcomes.  Proceeds of the loan will be ... of its products in the U.S. and ...
(Date:4/30/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that it will release first quarter ... after the close of the U.S. financial markets. The ... Thursday, May 7, 2015 at 4:30 p.m. Eastern / ... corporate developments. For both "listen-only" participants and ...
(Date:4/30/2015)... Rancho Cordova, CA (PRWEB) April 30, 2015 ... today announced that Julie I. Morris has joined SureClinical’s ... Morris is an experienced biotech and technology executive with ... to large Fortune 500 companies. , Ms. Morris ... California-based ag biotech company. She was CFO of MBI ...
(Date:4/29/2015)... GUELPH, ON , April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... twelve-month periods ended December 31, 2014. Biorem,s complete fiscal 2014 year-end financial ... FINANCIAL HIGHLIGHTS: 2014 , 2013 , 2014 ... 10,683 , 19,596 Gross profit 1,326 , ... 1,191 , 1,493 , 3,377 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... Rose Associates - Charleston, a leading retained executive ... promoted Bonnie R. Siegel as Partner of its ... information technology continues to be the fastest growing ... Bonnie will continue to focus on placing key ...
... This release is available in German . ... of DNA nanotechnology. This new discipline, which combines biology, physics, ... the natural DNA-strains, capacity for self assembly. Smileys or small ... meter) were created from DNA in a drop of water. ...
... Corporation, a leading developer of minimally invasive optical coherence ... has installed the first of its OCT Imaging Systems ... in Galveston, Texas. This first system sale ... Dr. Massoud Motamedi, Director, Center for Biomedical Engineering at ...
Cached Biology Technology:Sanford Rose Associates - Charleston Promotes Bonnie Siegel to Partner 2The world's smallest wedding rings 2Tomophase Announces First Sale of Its OCT Imaging System (OCTIS™) for Research Use to the University of Texas 2
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... at Linkping University previously developed ion transistors for transport ... biomolecules. Tybrandt has now succeeded in combining both transistor ... traditional silicon-based electronics. An advantage of chemical ... substances with various functions. This means that we now ...
... New research from Lund University in Sweden reveals the value ... dung beetles and the way their protective forewings actually function. ... beetles to lift off from the ground albeit at ... hardened structures which protect the insect,s flying wings and body. ...
... borders with colourful bedding plants, scientists at the Universities of ... attractive to bees rather than humans. Published today in the ... reveals that Velcro-like cells on plant petals play a crucial ... wind gets up., The study focuses on special cells found ...
Cached Biology News:Flapping protective wings increase lift 2Blowing in the wind: How hidden flower features are crucial for bees 2
... For knockdown of all human, ... siRNAs , Genomewide, predesigned siRNAs ... RNAi , Ready-to-use, convenient matching ... RT-PCR Cost-effective RNAi and ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
... CEQ 8800 Genetic Analysis System, which processes ... This automated system adds a higher level of ... CEQ 8800, part of Beckman Coulters new GenomeLab ... link with the Biomek series liquid handers, for ...
... for proteomic scale kinase profiling, quantitative measurement ... research built on the flexible and powerful ... are available as part of our comprehensive ... Probe Content Our standard ...
Biology Products: